Microbiota and immunotherapy: The birth of a new paradigm?
Cell Metabolism · 2026-07 · 38 (7) · 1269-1272
DOI: 10.1016/j.cmet.2026.06.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Metabolism, 2026-07. Verfasst von Rachel C Newsome und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Immunotherapy, Fecal Microbiota Transplantation, Neoplasms, Gastrointestinal Microbiome. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
Emerging data suggest fecal microbiota transplantation (FMT) may improve cancer patients' responses to immune checkpoint blockade not only by enriching beneficial bacteria but also by depleting harmful taxa. Here, we discuss the "supplementation" and new "depletion" FMT paradigms in cancer management and highlight key knowledge gaps to be addressed to move this field forward.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of Florida, Gainesville, FL, USA.
- Department of Medicine, University of Florida, Gainesville, FL, USA. Electronic address: christian.jobin@medicine.ufl.edu.
Zitieren
APA
Newsome, R. C., & Jobin, C. (2026). Microbiota and immunotherapy: The birth of a new paradigm?. Cell Metabolism, 38(7), 1269-1272. https://doi.org/10.1016/j.cmet.2026.06.007
Vancouver
Newsome RC, Jobin C. Microbiota and immunotherapy: The birth of a new paradigm?. Cell Metabolism. 2026;38(7):1269-1272. doi:10.1016/j.cmet.2026.06.007
BibTeX
@article{Newsome2026,
author = {Newsome, Rachel C and Jobin, Christian},
title = {Microbiota and immunotherapy: The birth of a new paradigm?},
journal = {Cell Metabolism},
year = {2026},
volume = {38},
number = {7},
pages = {1269--1272},
doi = {10.1016/j.cmet.2026.06.007}
}
EUVIMED